biopharmadive.com

Jazz Cancer Drug Clearance Could Drive Blockbuster Sales

Jazz Pharmaceuticals logoJazz Pharmaceuticals
Sig3.12Sen+5.63Env0.00Soc+3.44Gov+1.20

Use in that setting earned Jazz $24.8 million in revenue in 2025. The latest clearance could open a market opportunity above $1.5 billion, with analysts expecting relatively quick uptake. In Phase 3, Ziihera plus chemotherapy (with or without Tevimbra) cut progression or death by 35% and death by 28% versus Herceptin and chemo. Prescribing information endorses use for esophageal and stomach-esophagus junction tumors, potentially making about 12,000 U.S. patients eligible and driving $650 million to $700 million in U.S. gastroesophageal sales.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro